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Background: The PIK3CA gene mutation was found to associate with prognosis and might affect molecular
targeted therapy in esophageal carcinoma (EC). The aim of this study is to compare different methods for analyzing
the PIK3CA gene mutation in EC.
Methods: Genomic DNA was extracted from 106 surgically resected EC patient tissues. The PIK3CA mutation status
(exons 9 and 20) were screened by mutant-enrich liquid chip (ME-Liquidchip), Sanger sequencing, and pyrosequencing.
And all samples with mutations were independently reassessed using amplification refractory mutation system (ARMS)
methods again.
Results: PIK3CA mutation rates were identified as 11.3% (12/106) by ME-Liquidchip. 10 mutations occurred in exon 9 and
2 in exon 20, including G1624A:E542K (n = 4), G1633A:E545K (n = 6) and A3140G:H1047R (n = 2). The results were further
verified by ARMS methods. Among these 12 cases characterized for PIK3CA mutation, however, only 7 and 6 cases were
identified by Sanger sequencing (6.6%,7/106) and pyrosequencing (5.7%,6/106), respectively.
Conclusion: Sanger sequencing and pyrosequencing are less sensitive and are not efficiently applicable to the detection
of PIK3CA mutation in EC samples. Choosing between ME-Liquidchip and ARMS will depend on laboratory facilities and
expertise.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_153
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The phosphatidylinositol 3-kinase (PI3K) signaling path-
way has long been suggested to play a pivotal role in the
growth and survival of the cell, and pathway activation is
frequently found in the oncogenesis of human cancers
[1]. High frequencies of somatic mutations conferring
oncogenic potential have been found in the PIK3CA
gene, which encodes the PI3K catalytic subunit p110α
[2-7]. More than 30% of various solid tumor types were
found to contain the mutations, and it was frequently
mutated in cancers of the colon, breast, brain, liver, stom-
ach and lung [3,4,8]. Mutations in the three mutation* Correspondence: hxg@sjtu.edu.cn; houyingyong@hotmail.com
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unless otherwise stated.hotspots in PIK3CA (G1624A:E542K, G1633A:E545K, and
A3140G:H1047R) have been shown to elevate the lipid
kinase activity and thereby leading to the activation of the
downstream Akt signaling pathway [7]. Targeted therapies
such as Imatinib mesylate (anti-BCR/ABL and c-kit),
Gefitinib and Erlotinib (anti-EGFR) that appear to impart a
high degree of specificity for translocated/mutated onco-
genesis give hope that therapies targeted specifically against
mutant PIK3CA can be developed [5,9-12]. A recent report
extends previous studies suggesting that the acquisition of
PIK3CA mutations may be an important molecular event
in the etiology of esophageal cancer (EC) and the mutations
are associated with their clinical outcome [13-16].
The frequency of PIK3CA mutation in EC varied from
0% to 21%, which could likely introduce some bias in the
statistical analyses of their clinical significance [6,15-18].
The difference might be due to a difference in the patienttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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What’s more, somatic mutations of PIK3CA in EC sam-
ples are less than that observed in colorectal (18.8-32.0%)
and breast (8.3-40%) tumors [2,8,19]. Therefore, standard
methods with high sensitivity and speciality will be con-
ductive to examine the predictive and prognostic signifi-
cance of PIK3CA mutations in EC.
The first method used for mutation detection was dir-
ect Sanger sequencing of PCR products. However, it has
been limited in its ability to identify low levels of
mutation-bearing tumor cells [20,21]. The development
on new molecular techniques and the increased knowledge
of the genes implicated in the therapy response has boosted
the development of several new detection technology
including pyrosequencing, polymerase chain reaction-
restricted fragment length polymorphism (PCR-RELP),
Scorpion amplification refractory mutation system
(Scorpion-ARMS), length analysis of fluorescently la-
beled polymerse chain reaction (PCR), denaturing
high-performance liquid chromatography (DHPLC),
and mutant-enrich liquid chip (ME-Liquidchip). However,
uncertainty exists regarding which detection method can
be applied in a reproductive, sensitive, and simple manner
in the routine diagnostic setting. In previous studies, re-
searchers compared the detection rate of PIK3CA, EGFR,
KRAS and BRAF mutation in colorectal or lung cancers by
different methods [22-25]. To our knowledge, no compara-
tive assessment of these novel technologies has been avail-
able in EC up until now.
In this study, we compare four different methods of
PIK3CA mutation ananlysis: Sanger sequencing, pyrose-
quencing, ME-Liquidchip and ARMS.Methods
Patients and tissue samples
106 patients with esophageal cancer were recruited
from March to October 2010 with the assistance of the
Department of Thorax Surgery, Zhongshan Hospital.
All samples without any treatment preoperatively were
obtained intraoperatively during esophagetomy resec-
tion at our Hospital. Prior written informed consent
was provided from all patients and the study protocol
received ethics board approval at the Zhongshan hos-
pital, Fudan University.
Tissues were fixed in 10% buffered formalin within
30 minutes after resection and processed following the
routine procedure after 24 hours fixation. Sections were
stained with hematoxylin and eosin (H&E) and reviewed
by two pathologists to confirm the EC diagnosis. Then,
the following patient characteristics were collected for
the 106 EC patients, including gender, age, tumor site,
histological grade, depth of infiltration lymph node me-
tastasis, and stage [26].Genomic DNA extraction from formalin-fixed paraffin-
embedded (FFPE) tissue
FFPE tumor blocks were reviewed for quality and tumor
content. A single representative block, containing at least
70% of neoplastic cells, was selected for DNA extraction.
Genomic DNA was extracted using the QIAamp Mini kit
(Qiagen) according to the manufacturer’s instructions. The
extracted DNA was stocked at −20°C for posterior analysis.
Sanger sequencing
DNA fragments corresponding to exon 9 and 20 of the
PIK3CA gene were amplified by PCR. The primers for
exon 9 of PIK3CA gene were GTCTTAGATTGGTT
CTTTCCTG for forward and GCATT TAATGTGC
CAACTACC for reverse, for exon 20 of PIK3CA gene
were TTTGTCTACGAAAGCCTCTCTA for forward
and CCATCACTTTTTCCTTCTCCAT for reverse. The
PCR products were purified using the PCR purification kit
(Axygen) and checked on 2% agarose gel electrophoresis.
Sequencing was performed by applying the same forward
and reverse primers and using the Big Dye ®terminator se-
quencing kit version 3.0 (Life Technologies) on a 3130 gen-
etic analyzer (Life Technologies). The sequencing results
were interpreted using Chromas software.
Pyrosequencing
PCR was carried out with Takara hotstart Taq. The PCR
products were then prepared with the Vacuum Prep
workstation (Biotage AB, Uppsala, Sweden) according to
the following protocol: 40 μl of the amplicon, 3 μl strep-
tavidin Sepharose HP beads (GE Healthcare), 37 μl binding
buffer and 15 μl Milli-Q water were mixed for 5–10 min.
The biotinylated amplicons were immobilized onto the
streptavidin Sepharose beads, washed by 70% ethnol, dena-
tured by 0.2 mol/l NaOH, and washed by water using the
Vacuum Prep workstation. The amplicons were transferred
to a plate containing 0.4 μmol/l corresponding sequencing
primer in 40 μl annealing buffer. For exon 9, the sequen-
cing primer is PIK3CA-9-S (AAGCAATTTCTACAC
GAG); for exon 20, the sequencing primer is PIK3CA-20-
S (GGCTTTGGAGTATTTCAT). Heat the plate with the
samples at 80°C for 2 min. Pyrosequencing was performed
using the PyroMark Gold Q96 Reagent and the PyroMark
ID system (QIAGEN). The results were compared with
the sequences of human PIK3CA gene in National Center
for Biotechnology Information. All mutations were veri-
fied at least twice, as were the normal controls.
Mutant-enriched liquidchip technology (ME-Liquidchip)
The ME-Liquidchip method includes three major steps:
1) introduction of a restriction site to the wild-type or
mutant DNA through PCR amplification to eliminate
the wild-type genes by restriction enzyme digestion;
2) selective amplification of the mutated DNA sequence;
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probe, which is precoated on the polystyrene microspheres
and analyzed using the Luminex (xMAP) analyzer
(Luminex Co.) In this method, the wild-type DNA
could not be completely digested after the first round
of PCR. However, after digestion, the ratio of mutant
to wild-type DNA was dramatically increased. Therefore,
the mutant PCR product after the 2nd PCR could be
detected using the Luminex analyzer. Primers were de-
signed against the sequences of codon 542, 545 and
1047 in the PIK3CA gene. Following PCR amplification,
3 uL of PCR product was transferred to 96-well plates
for Hybridization, which contained 37 uL of the
hybridization solution (SurExam, China) and a mixture
of 1000 probe-coated beads of each type of mutation
(H1047L, H1047R, E542K, E545K, E545D). The hybridized
beads were analyzed using a Luminex 200 analyzer and the
median reporter fluorescence intensity (MFI) was com-
puted for each bead set in the samples. Screening was
performed by SurExam Bio-Tech Co. Ltd. (Guangzhou
Technology Innovation Base, Science City, Guangzhou, P.R
China).
ARMS analysis of samples with PIK3CA mutation detected
by other methods
DNA samples from the same preparation for PCR direct
sequencing analysis were subjected to PIK3CA mutant ana-
lysis using AmoyDx (r) PIK3CA Five Mutations Detection
Kit (Amoy Diagnostics Co.Ltd). The kit contains primers
designed for detection of 5 common PIK3CA mutations
based on ARMS PCR (amplification refractory mutation
specific PCR) and double circular probe detection technol-
ogy. The analysis was carried out as described in the oper-
ation instruction of the kit.
Statistical analysis
The agreement for genotype PIK3CA mutational was mea-
sured by the index kappa [27] calculated using SPSS soft-
ware version 15, and Statistical differences were analyzed
by the McNemar test [28] and p value less than 0.05 was
recorded as significant.
Results
Characterization of EC patients
A total of 106 EC samples obtained from primary tumors.
The age of the patients ranged from 37 to 81 years with a
median of 62 years of age. There were 88 males and 18 fe-
males. There were 1 tumor in upper, 37 in middle and 68
in lower sites. Histologically, 96 cases were squamous cell
carcinoma (SCC), 2 cases were adenosquamous cell carcin-
oma (ASCC), 2 were basoid squamous cell carcinoma
(BSCC), 3 cases were neuroendocrine carcinoma (NEC), 3
cases were composition of SCC and NEC. No pure adeno-
carcinoma was identified in our collection. Based on celldifferentiation, 61 were graded as II, 30 were III and 5 were
IV, the other cases were non-ESCC. Six cases in stage IB,
31 in stage IIA, 25 in stage IIB, 22 in stage IIIA, 19 in stage
IIIB, and 3 in stage IIIC.
Gene mutation analysis
PIK3CA mutations on exons 9 and 20 were analyzed in
106 esophageal carcinoma patients by Sanger sequen-
cing, pyrosequencing, ME-Liquidchip. All the mutant
samples detected were further assessed using ARMS.
The examples of date adquisition by the different
methods are shown in Figure 1. PIK3CA mutations rates
were 5.7% (6/106), 6.6% (7/106) and 11.3% (12/106) by
Sanger sequencing, pyrosequencing, and ME-Liquidchip
respectively. The subset of 12 samples displaying mutant
sequences were detected by ARMS, and the results were
consistent with ME-Liquidchip method. The results are
shown in Table 1. PIK3CA mutation spectrum was simi-
lar in all 4 approaches with the exception that exon 20
mutation (representing approximately 16.7% of the mu-
tations according to ME-Liquidchip and ARMS) were
not detected by pyrosequencing. We used different stat-
istical approaches to compare methods (Tables 2 and 3).
Overall, concordance between Sanger sequencing and
pyrosequencing was high, but ME-Liquidchip did not
correlate well with any of the alternative methods. The
later was basically due to the fact that 5–6 samples
displaying wildtype sequences appear to be mutated by
ME-liquidchip and ARMS. The detection percentage of
PIK3CA mutation by ME-Liquidchip was higher than
that of Sanger sequencing and pyrosequencing, this differ-
ence was statistically significant (p < 0.05, respectively).
Three discrepancies were observed between Sanger se-
quencing and pyrosequencing. Two samples (EC037 and
EC058) carried mutations according to Sanger sequencing,
but were negative according to pyrosequencing. On the
contrary, one sample (EC095) was negative according to
Sanger sequencing, but carried a mutation according to
pyrosequencing. These mutations were detected as well by
ME-liquidchip and ARMS.
Discussion
The knowledge of the mutational status of many genes
implicated in response to the therapy (KIT, EGFR, BRAF,
KRAS, PI3K, etc.) [29-31] is a real fact in the clinical
management of the patients. By combining the copious
amount of sequencing data over the past year, we find
that the PIK3CA gene is one of the two most commonly
mutated genes identified in human cancers (the other
being KRAS) [2-4,6,8]. In most tissue types, mutations pre-
dominantly cluster within the helical and kinase domains of
the PIK3CA subunit. Exon 9 mutations are located in the
helical domain of p110a and are considered to abrogate in-
hibitory intermolecular interaction between p85 and p110.
Table 1 PIK3CA mutation status determined by different methods
Methods ME-Liquidchip ARMS Sanger sequencing Pyrosequencing
Case no Nucleotide Amino acid Nucleotide Amino acid Nucleotide Amino acid Nucleotide Amino acid
EC011 G1624A E542K G1624A E542K G1624A E542K G1624A E542K
EC030 G1633A E545K G1633A E545K G1633A E545K G1633A E545K
EC037 A3140G H1047R A3140G H1047R A3140G H1047R WT unchanged
EC039 G1624A E542K G1624A E542K G1624A E542K G1624A E542K
EC041 G1624A E542K G1624A E542K G1624A E542K G1624A E542K
EC053 G1624A E542K G1624A E542K WT unchanged WT unchanged
EC058 G1633A E545K G1633A E545K G1633A E545K WT unchanged
EC060 G1633A E545K G1633A E545K G1633A E545K G1633A E545K
EC070 A3140G H1047R A3140G H1047R WT unchanged WT unchanged
EC074 G1633A E545K G1633A E545K WT unchanged WT unchanged
EC084 G1633A E545K G1633A E545K WT unchanged WT unchanged
EC095 G1633A E545K G1633A E545K WT unchanged G1633A E545K
Figure 1 Representative results for PIK3CA exon 9 and 20 mutation analysis. EC058 (A) and EC037 (B) were detected
harboring E545K and H1047R mutation using Sanger sequencing and ARMS, but the same samples were considered wt according
to pyrosequencing.
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ME-Liquidchip ME-Liquidchip Sanger sequencing
Sanger sequencing WT Mut Total Pyrosequencing WT Mut Total Pyrosequencing WT Mut Total
WT 94 5 99 WT 94 6 100 WT 99 1 100
Mut 0 7 7 Mut 0 6 6 Mut 0 6 6
Total 94 12 106 Total 94 12 106 Total 99 7 106
The McNemar Test, ME-Liquidchip vs Sanger sequencing, ME-Liquidchip vs Prosequencing, Sanger sequencing vs Prosequencing were, respectively, 5.25
(p < 0.025), 6.36 (p < 0.025) and 1.01 (p > 0.25).
Wt, wild type; Mut, mutant.
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tion loop and are considered to produce constitutive kinase
activity. Many researchers suggested that these genetic al-
terations may be kinase activating and oncogenic in differ-
ent human malignant tumors, including colon, breast
cancer, endometrial, lung, and brain tumors [32-37]. Re-
cently, Song and Lin identified PIK3CA mutations in EC
with whole-genome sequencing, whole-exome sequencing
or array comparative genomic hybridization analysis, and
suggested their functional relevance in EC [13,14]. On the
other hand, the use of some potent PI3K/mTOR inhibitors,
even nonsteroidal anti-inflammatory drugs (NSAID) was
thought associate with longer survival among patients with
mutated-PIK3CA colorectal cancer, but not among patients
with wild-type PIK3CA cancer [38-41]. Therefore, PIK3CA
mutation screening would greatly improve therapeutic
strategies for EC in the future.
According to the current study, the different methods
used in examination provide different mutation results,
such as KRAS and EGFR in the same samples [22,42].
Several methods have been applied to detection of
PIK3CA gene mutation in EC [15,17,18,43], it is neces-
sary to compare the assays.
Until recently, the gold standard and most widely
available method for mutation detection was Sanger se-
quencing, which is the only approach that permits to de-
tect all possible sequence variants present in the target
sequence, but it has several drawbacks. In particular, it is
time consuming and has low sensitivity (20–50%) for the
detection of mutant cells in FFPE tissue. Moreover,
subjective interpretation is difficult to avoid if signal/
noise ratio is low. Pyrosequencing is a sequencing-by-Table 3 Concordance between the three methods used









The results of mutational analysis by Sanger sequencing were in agreement
with Pyrosequencing k = 0.75. The scores of both methods were in poor
concordance with ME-Liquidchip k = 0.71 vs to Sanger sequencing and k = 0.64 vs
to Prosequencing.(values in brackets are the 95% CI for the k statistic).synthesis approach based on sequential addition of dNTPs
followed by release of a pyrophosphate molecule that differs
from the chain termination dye of the Sanger method, and
particularly efficient for investigating mutations in short
sequences. So pyrosequencing assay for PIK3CA mutation
detection is certainly useful, because most activating
PIK3CA mutations cluster in the hotspots of exons 9 and
20. In some cohort the minimum of mutated alleles de-
tected with pyrosequencing was 5%. The ARMS kit has
many advantages, including a closed system to prevent con-
tamination, fast turnaround time (which may be relevant in
some clinical situations), user-friendly, software-assisted
data interpretation that prevents subjective interpretation.
ME-Liquidchip is a novel technology, which integrates the
sensitive mutant enriched PCR and quantitative high-
throughput liquidchip (suspension array) to detect DNA
somatic mutations in EGFR, KRAS, BRAF, and PIK3CA
genes from tissues or serum samples. It has been reported
that ME-Liquidchip is capable of detecting as few as 20
copies of mutant alleles with a sensitivity limit of at least
mutant: wild-type ratio of 0.1%.
Here, we report our study of PIK3CA mutations by
Sanger sequencing, pyrosequencing, ME-Liquidchip and
ARMS in a clinical setting. With 106 EC samples, a total
of 12 PIK3CA mutations were identified. The prevalence
and distribution of PIK3CA mutations found in our
study by ME-Liquidchip (11.3%) were in agreement with
previous data reported in esophageal cancer [16,17,43].
All mutations were independently reassessed by ARMS.
ME-Liquidchip and ARMS detected five mutated cases
were not found by Sanger sequencing and pyrosequencing
and they detect all mutations that had been detected by the
other two methods, suggesting a higher sensitivity.
As to Sanger sequencing and pyrosequencing, the
detected rate of PIK3CA mutation was 6.6% and 5.7%,
respectively. Sanger sequencing detected two tumors
harboring E545K and H1047R mutation, but the same sam-
ples were considered wt according to pyrosequencing. On
the contrary, a tumor harboring a E545K mutation in terms
of pyrosequencing was not detected by Sanger sequen-
cing. Because the three mutations were detected by
ME-Liquidchip and ARMS, we are pretty sure that they
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quencing. Interestingly, the mutation frequency detected by
Sanger sequencing is slightly higher compared with that of
pyrosequencing. In previous study, the latter was consid-
ered to be with the very high sensitivity [15,24,42]. Most
probably, they reflect problems related to low tumor DNA
enrichment in the sample or the predesigned kit.
On cost-effectiveness grounds, Sanger sequencing is
the method with the better defined track record and is
the least expensive, relying on instruments and cheap
reagents that are widely available. Pyrosequencing, ME-
Liquidchip and ARMS require expensive reagents and
consumables along with purchase or lease of specific
instruments required by the different kits. The cost-
effectiveness ratio of molecular diagnostic tests depends
on a number of factors that can vary considerably,
depending on the characteristics of each molecular diag-
nostic laboratory or the demands of specific institutions.
It is important to point out that we have performed our
analysis in a consecutive series of 106 EC tumor sam-
ples, corresponding to the everyday practice of most mo-
lecular diagnostic laboratories.
It’s reported there was an different distribution of
PIK3CA mutations between adenocarcinoma and SCC
histological subtypes of EC [16,43]. However, all our
detected mutant samples were esophageal SCC. Strik-
ing variation in geographical distribution may be the
reason. It’s known to us, esophageal SCC is the pre-
dominant histological type in Asian areas, in contrast,
esophageal adenocarcinoma is the predominant histo-
logical in Western countries [44]. Our study is retro-
spective, the results still need to be further confirmed
by more investigation.Conclusion
To conclude, this is so far the only study comparing these
four molecular methods in EC. We have demonstrated that
ME-Liquidchip and ARMS is highly sensitive for clinical
diagnosis of PIK3CA mutation in EC. Using these methods,
we found significant statistical numbers of mutated cases
that were not detected by Sanger sequencing and pyrose-
quencing, and these results may contribute to therapeutic
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